Pipeline

NKMax is conducting numerous clinical trials to discover how natural killer (NK) cells can help patients with cancer, autoimmune disease and neurodegenerative conditions.

SNK01, NKMax’s first cell therapy candidate, has planned clinical trials in several therapeutic areas, including oncology, autoimmune disease and neurodegeneration. This approach allows us to evaluate the potential benefits of adoptive cellular immunotherapy for multiple biologically relevant disease areas.

Oncology

Preclinical

Phase I

Phase II

Phase III

Stage IV Non Small Cell Lung Cancer

SNK01 + Keytruda (pembrolizumab)

Active, Phase I/IIa

Refractory Solid Tumors

Single Agent SNK01

Active, Phase I

Localized/Metastatic Sarcoma (Orphan Disease)

Single Agent SNK01

In Planning, Phase II

Stage I-III Triple Negative Breast Cancer

Single Agent SNK01

In Planning, Phase II

Refractory HER2+Solid Tumors

SNK01 + Herceptin (trastuzumab)

In Planning, Phase I

Refractory EGFR + Solid Tumors

SNK01 + Erbitux (cetuximab)

In Planning, Phase I

Active
Active
In Planning
In Planning
In Planning
In Planning

Autoimmune Diseases

Preclinical

Phase I

Phase II

Phase III

Mild to Severe Psoriasis

Single Agent SNK01

Active, Phase I

Rheumatoid Arthritis

Single Agent SNK01

In Planning, Phase I

Primary Progressive and Relapsing-Remitting Multiple Sclerosis

Single Agent SNK01

In Planning, Phase I

Moderate to Severe Psoriasis Refractory to Biologic Therapy

Single Agent SNK01

In Planning, Phase II

Active
In Planning
In Planning
In Planning

Neurodegenerative Diseases

Preclinical

Phase I

Phase II

Phase III

Mild to Severe Alzheimer’s Disease

Single Agent SNK01

In Planning, Phase I

Mild to Severe Alzheimer’s Disease

Single Agent SNK01

In Planning